Iovance Biotherapeutics, Inc.
IOVA
Rankning i aktier
#2784
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aktiekurs
$14.79
Marknadsvärde
$6.70B
Förändring (1 dag)
-0.47%
Förändring (1 år)
551.54%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)
Kategori
Healthcare
P/B-tal för Iovance Biotherapeutics, Inc. (IOVA)
P/B-tal per October 2026 TTM: 8.69
Enligt Iovance Biotherapeutics, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 8.69. I slutet av 2023 hade företaget ett P/B-tal på 3.27.
Historik för P/B-tal för Iovance Biotherapeutics, Inc. från 2008 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 8.69 | 187.79% |
| 2024 | 3.02 | -7.66% |
| 2023 | 3.27 | 60.54% |
| 2022 | 2.04 | -56.76% |
| 2021 | 4.71 | -51.81% |
| 2020 | 9.77 | -15.09% |
| 2019 | 11.51 | 523.36% |
| 2018 | 1.85 | -48.53% |
| 2017 | 3.59 | 55.91% |
| 2016 | 2.30 | -30.18% |
| 2015 | 3.30 | -24.84% |
| 2014 | 4.38 | -24.70% |
| 2013 | 5.82 | -475.21% |
| 2012 | -1.55 | -73.87% |
| 2011 | -5.94 | -104.65% |
| 2010 | 127.82 | -101.69% |
| 2009 | -7.55K | -112.90% |
| 2008 | 58.49K | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -28.08% |
US
|
|
| 13.2547 | 52.51% |
US
|
|
| 4.208 | -51.58% |
AU
|
|
| 6.1824 | -28.87% |
NL
|
|
| - | - |
CH
|
